v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net sales $ 5,442,000,000 $ 5,061,000,000 $ 10,646,000,000 $ 9,724,000,000
Cost of products sold (excluding amortization expense) 1,594,000,000 1,637,000,000 3,184,000,000 3,090,000,000
Gross profit 3,848,000,000 3,424,000,000 7,462,000,000 6,633,000,000
Operating expenses:        
Selling, general and administrative expenses 1,803,000,000 1,716,000,000 3,583,000,000 3,312,000,000
Research and development expenses 554,000,000 526,000,000 1,069,000,000 969,000,000
Royalty expense 12,000,000 14,000,000 24,000,000 28,000,000
Amortization expense 233,000,000 225,000,000 466,000,000 444,000,000
Intangible asset impairment charges 0 46,000,000 0 46,000,000
Contingent consideration net expense (benefit) (16,000,000) (5,000,000) (46,000,000) 0
Restructuring net charges (credits) 8,000,000 83,000,000 11,000,000 93,000,000
Litigation-related net charges (credits) 76,000,000 0 76,000,000 0
Operating expenses 2,670,000,000 2,605,000,000 5,183,000,000 4,894,000,000
Operating income (loss) 1,178,000,000 819,000,000 2,279,000,000 1,740,000,000
Other income (expense):        
Interest expense (96,000,000) (90,000,000) (186,000,000) (172,000,000)
Other, net (23,000,000) 213,000,000 129,000,000 179,000,000
Income (loss) before income taxes 1,060,000,000 941,000,000 2,222,000,000 1,746,000,000
Income tax expense (benefit) 155,000,000 146,000,000 (21,000,000) 279,000,000
Net income (loss) 905,000,000 795,000,000 2,243,000,000 1,467,000,000
Net income (loss) attributable to noncontrolling interests (2,000,000) (2,000,000) (4,000,000) (4,000,000)
Net income (loss) attributable to Boston Scientific common stockholders $ 907,000,000 $ 797,000,000 $ 2,247,000,000 $ 1,471,000,000
Net income (loss) per common share — basic $ 0.62 $ 0.54 $ 1.52 $ 0.99
Net income (loss) per common share — diluted $ 0.61 $ 0.53 $ 1.51 $ 0.98
Weighted-average shares outstanding        
Basic 1,470.2 1,479.9 1,477.6 1,478.5
Diluted 1,474.8 1,493.5 1,484.9 1,493.3